Oncotarget

Research Papers:

Interferon-induced transmembrane protein 1 (IFITM1) is required for the progression of colorectal cancer

Ita Novita Sari, Ying-Gui Yang, Lan Thi Hanh Phi, Hyungjoo Kim, Moo Jun Baek, Dongjun Jeong and Hyog Young Kwon _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:86039-86050. https://doi.org/10.18632/oncotarget.13325

Metrics: PDF 1861 views  |   HTML 2413 views  |   ?  


Abstract

Ita Novita Sari1,*, Ying-Gui Yang1,*, Lan Thi Hanh Phi1, Hyungjoo Kim2, Moo Jun Baek3, Dongjun Jeong2, Hyog Young Kwon1

1Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Republic of Korea

2Soonchunhyang Medical Science Research Institute, College of Medicine, Soonchunhyang University, Republic of Korea

3Department of Surgery, Department of Pathology, College of Medicine, Soonchunhyang University, Republic of Korea

*These authors contributed equally to this work

Correspondence to:

Hyog Young Kwon, email: [email protected]

Dongjun Jeong, email: [email protected]

Keywords: IFITM1, colorectal cancer, prognosis, metastasis

Received: June 06, 2016     Accepted: November 07, 2016     Published: November 12, 2016

ABSTRACT

Interferon-induced transmembrane protein 1 (IFITM1) has been shown to be implicated in multiple cancers, yet little is known about biological significance of IFITM1 in colorectal cancer. Here, we show that IFITM1 is highly expressed in metastatic colorectal cancer cell lines as well as colorectal patient-derived tumor samples, and its expression is associated with a poor prognosis of the disease. Also, IFITM1 depletion resulted in a significant reduction in the mobility of cancer cell lines, whereas ectopic expression of IFITM1 promoted the migration of cancer cells. Epithelial-mesenchymal transition (EMT) signature was dysregulated by both loss and gain of function of IFITM1, which was partially reverted by Caveolin-1 (CAV1). Therefore, these results suggest that IFITM1 may be a prognostic marker and an attractive target to achieve better therapeutic outcomes in colorectal cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13325